Gretchen Campbell, MD
Neurology · Franklin, TNNPI 1225125354
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $27,460 of the $33,980 with a category attached, or 80.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $11,300 and has fallen 67.7% since, to $3,651 in 2025.
Across 1,533 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$8K
- AbbVie$2K
- Novartis$2K
- Biogen$2K
- Teva Pharmaceuticals USA, Inc.$1K
- EMD Serono, Inc.$1K
- plus $17K from 54 others
Across 148 payments — averaging $5786.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$480K
- Eli Lilly$121K
- E.r. Squibb & Sons, L.L.C.$69K
- Sanofi$47K
- Biohaven Pharmaceutical Holding Company Ltd.$31K
- Pfizer$27K
- plus $81K from 6 others
What the payments were for
- Consulting fees$4,20012%
- Travel & lodging$1,8015%
- Food & beverage$27,46081%
- Education$5192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,980 in reported general payments places this provider in the 85th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 65 | $543,203 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 15 | $316,286 |
| BotoxOnabotulinumtoxina | 116 | $161,842 |
| Everolimus | 13 | $111,069 |
| Nurtec OdtRimegepant Sulfate | 23 | $44,558 |
| Aimovig AutoinjectorErenumab-Aooe | 44 | $37,985 |
| Emgality PenGalcanezumab-Gnlm | 31 | $33,253 |
| UbrelvyUbrogepant | 25 | $30,294 |
| RexultiBrexpiprazole | 12 | $23,414 |
| NeuproRotigotine | 24 | $19,065 |
| QuliptaAtogepant | 16 | $17,056 |
| NamzaricMemantine Hcl/Donepezil Hcl | 18 | $13,634 |
| Pregabalin | 111 | $8,841 |
| Lamotrigine ErLamotrigine | 30 | $7,115 |
| Lisdexamfetamine Dimesylate | 16 | $3,404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $518 | $543,20365 claims |
| PfizerPanzyga, Nurtec Odt | $539 | $360,84338 claims |
| AbbVieBotox, Ubrelvy, Qulipta, Namzaric | $2,442 | $222,826175 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $149 | $23,41412 claims |
| UCB, Inc.Neupro | $888 | $19,06524 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $133 | $70211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 361 neurology providers in Tennessee.
Other neurology in Franklin
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
- Lucas ElijovichMemphis$415K
- David BrandesKnoxville$412K
- Sibyl WrayKnoxville$377K
- Christine HagenAlcoa$371K
- Mark LedouxMemphis$352K
- Christopher PendolaKingsport$344K
- Daniel ClaassenNashville$285K
- Khalid AlsherbiniMemphis$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.